Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Spark Therapeutics Inc.
Headquarters: Philadelphia, PA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Feb 27, 2025
Product Development
Editas: The high-risk, high-reward gene editing pioneer
Editas set out to bring a new technology — CRISPR-Cas9 — to indications not served by existing therapeutic modalities
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 4, 2025
Emerging Company Profile
Mirai: One-stop shop for genetic medicine developers
With $50M from Flagship, Mirai is optimizing nucleic acid design, delivery and manufacturing for clients
BioCentury | Oct 11, 2024
Finance
City is location of Maraganore’s next RNAi play
BioCentury’s latest Venture Report includes rounds for Judo, Purespring, Basecamp, Arda and more
BioCentury | Sep 10, 2024
Management Tracks
Lucas Montarce named Lilly CFO
Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more
BioCentury | Jul 10, 2024
Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | Apr 30, 2024
Management Tracks
Innovent hires Gracell vet Samuel Zhang as CBO
Plus: CEO changes at Lexicon, Avacta and Sphere Fluidics, and updates from Generate, Charm, ViaNautis and more
BioCentury | Feb 6, 2024
Product Development
Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more
Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
BioCentury | Nov 3, 2023
Finance
Lexeo cuts IPO price, becomes latest to lose value in first session
With gene therapy company’s dip Friday, seven of 10 major 2023 NASDAQ biotech listings have now traded down in the aftermarket since pricing
BioCentury | Oct 17, 2023
Deals
Oct. 17 Quick Takes: Monte Rosa gets $50M in molecular glue deal with Roche
Plus: Gilead options Assembly’s antiviral pipeline and updates from KKR, Catalio, Roche, SpliceBio, VedaBio, Merck, Nuvalent, Tessellate, Amplifier and Evelo
Items per page:
1 - 10 of 266